Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
Gut
    June 2024
  1. KEGGENHOFF FL, Castven D, Becker D, Stojkovic S, et al
    PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.
    Gut. 2024 Jun 10:gutjnl-2023-331237. doi: 10.1136/gutjnl-2023-331237.
    >> Share

  2. BU L, Zhang Z, Chen J, Fan Y, et al
    High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT.
    Gut. 2024;73:1156-1168.
    >> Share

  3. NISCHALKE HD, Nischalke C, Schmalz F, Moller C, et al
    Catecholamines and inflammation in advanced liver disease: more closely intertwined than expected?
    Gut. 2024;73:1219-1222.
    >> Share

  4. CHEN A, Zhang VX, Zhang Q, Sze KM, et al
    Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma.
    Gut. 2024 Jun 5:gutjnl-2024-331903. doi: 10.1136/gutjnl-2024-331903.
    >> Share

    May 2024
  5. BABUTA M, Morel C, de Carvalho Ribeiro M, Calenda C, et al
    Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis.
    Gut. 2024 May 22:gutjnl-2023-331447. doi: 10.1136/gutjnl-2023-331447.
    >> Share

  6. WEN J, Zhang X, Wong CC, Zhang Y, et al
    Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma.
    Gut. 2024 May 13:gutjnl-2023-331117. doi: 10.1136/gutjnl-2023-331117.
    >> Share

  7. GEIER A, Trost J, Wang K, Schmid C, et al
    PNPLA3 fatty liver allele was fixed in Neanderthals and segregates neutrally in humans.
    Gut. 2024;73:1008-1014.
    >> Share

  8. ISRAELSEN M, Alvarez-Silva C, Madsen BS, Hansen CD, et al
    Impact of acute alcohol consumption on circulating microbiome in asymptomatic alcohol-related liver disease.
    Gut. 2024;73:1041-1044.
    >> Share

  9. ROCA SUAREZ AA, Plissonnier ML, Grand X, Michelet M, et al
    TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism.
    Gut. 2024 May 2:gutjnl-2023-331396. doi: 10.1136/gutjnl-2023-331396.
    >> Share

    April 2024
  10. BREITKOPF-HEINLEIN K, Martinez-Chantar ML
    Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?
    Gut. 2024 Apr 25:gutjnl-2023-331785. doi: 10.1136/gutjnl-2023-331785.
    >> Share


  11. Correction: Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.
    Gut. 2024 Apr 23:gutjnl-2016-312278corr1. doi: 10.1136/gutjnl-2016-312278.
    >> Share

  12. SUDDLE A, Reeves H, Hubner R, Marshall A, et al
    British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.
    Gut. 2024 Apr 16:gutjnl-2023-331695. doi: 10.1136/gutjnl-2023-331695.
    >> Share

  13. LIU J, MacNaughtan J, Kerbert AJC, Portlock T, et al
    Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbab le, gut-restricted adsorbent in models and patients with cirrhosis.
    Gut. 2024 Apr 15:gutjnl-2023-330699. doi: 10.1136/gutjnl-2023-330699.
    >> Share

  14. SUISSA S, Hernaez R
    Glucagon-like peptide-1 receptor agonists to treat chronic liver disease: real-world evidence or ambiguity?
    Gut. 2024;73:721-724.
    >> Share

  15. LIU B, Peng G, Yin Y, Shen C, et al
    Genetic evidence for repurposing of glucagon-like peptide-1 receptor agonists to prevent chronic liver diseases.
    Gut. 2024;73:879-882.
    >> Share

  16. WESTER A, Shang Y, Toresson Grip E, Matthews AA, et al
    Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes.
    Gut. 2024;73:835-843.
    >> Share

  17. ARMANDI A, Sanavia T, Younes R, Caviglia GP, et al
    Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
    Gut. 2024;73:825-834.
    >> Share

    March 2024
  18. TREBICKA J, Hernaez R, Shawcross DL, Gerbes AL, et al
    Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.
    Gut. 2024 Mar 25:gutjnl-2023-330584. doi: 10.1136/gutjnl-2023-330584.
    >> Share

  19. HILDT E, Hu J
    New facet of CARs: HBV-specific CARs as inhibitors of virus morphogenesis and release.
    Gut. 2024;73:566-567.
    >> Share

  20. TARGHER G, Byrne CD, Tilg H
    MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
    Gut. 2024;73:691-702.
    >> Share

    February 2024
  21. LEE HH, Lee HA, Kim EJ, Kim HY, et al
    Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease.
    Gut. 2024;73:533-540.
    >> Share

  22. CUBERO FJ, Sarobe P, Tiegs G
    Advancing with cancer immunotherapeutics: CD29(+) regulatory T cell antagonism.
    Gut. 2024;73:391-392.
    >> Share

  23. GREEN BL, Myojin Y, Ma C, Ruf B, et al
    Immunosuppressive CD29(+) Treg accumulation in the liver in mice on checkpoint inhibitor therapy.
    Gut. 2024;73:509-520.
    >> Share

  24. HUNTER H, Johnston AJ, Said W, Wong NA, et al
    Colonic spider naevi in a middle-aged man.
    Gut. 2024;73:441-520.
    >> Share

  25. QIAN Z, Liang J, Huang R, Song W, et al
    HBV integrations reshaping genomic structures promote hepatocellular carcinoma.
    Gut. 2024 Feb 23:gutjnl-2023-330414. doi: 10.1136/gutjnl-2023-330414.
    >> Share

  26. EL-SERAG H, Kanwal F, Ning J, Powell H, et al
    Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.
    Gut. 2024 Feb 16:gutjnl-2024-332034. doi: 10.1136/gutjnl-2024-332034.
    >> Share

  27. KEATING CR, Calvisi DF, Qiu W
    High-fat diet-induced AKT-palmitoylation in hepatocellular carcinoma: a breakthrough mechanistic investigation.
    Gut. 2024 Feb 9:gutjnl-2023-331857. doi: 10.1136/gutjnl-2023-331857.
    >> Share

    January 2024
  28. HE T, Zhang D
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B: still needs further discussion.
    Gut. 2024 Jan 22:gutjnl-2023-331443. doi: 10.1136/gutjnl-2023-331443.
    >> Share

  29. BARCENA-VARELA M, Berraondo P
    Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma.
    Gut. 2024 Jan 9:gutjnl-2023-331647. doi: 10.1136/gutjnl-2023-331647.
    >> Share


  30. Correction: P23 Opportunistic cirrhosis case finding in alcohol dependent inpatients through alcohol specialist nurse assessment and transient elastography: early detection in a high-risk group.
    Gut. 2024;73:e3.
    >> Share

  31. KONG M, Zhou J, Kang A, Kuai Y, et al
    Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis.
    Gut. 2024 Jan 4:gutjnl-2023-329671. doi: 10.1136/gutjnl-2023-329671.
    >> Share

    December 2023
  32. YANG TC, Chen WC, Hou MC, Chen PH, et al
    Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial.
    Gut. 2023 Dec 14:gutjnl-2023-330419. doi: 10.1136/gutjnl-2023-330419.
    >> Share

  33. CAI N, Cheng K, Ma Y, Liu S, et al
    Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8(+) T cell-mediated antitumour immunity and improves anti-PD-1 efficacy.
    Gut. 2023 Dec 13:gutjnl-2023-331342. doi: 10.1136/gutjnl-2023-331342.
    >> Share

  34. HEINEN N, Khanal R, Westhoven S, Klohn M, et al
    Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses.
    Gut. 2023 Dec 12:gutjnl-2023-330961. doi: 10.1136/gutjnl-2023-330961.
    >> Share

  35. YU X, Pfefferkorn M, van Bommel F, Zhang X, et al
    Clinical applications of circulating HBV RNA as a potential surrogate biomarker for intrahepatic cccDNA transcriptional activity.
    Gut. 2023 Dec 11:gutjnl-2023-331217. doi: 10.1136/gutjnl-2023-331217.
    >> Share

  36. CHOUIK Y, Levrero M
    Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block.
    Gut. 2023;73:10-11.
    >> Share

    November 2023
  37. LI R, Liu X, Huang X, Zhang D, et al
    Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis.
    Gut. 2023 Nov 30:gutjnl-2023-330243. doi: 10.1136/gutjnl-2023-330243.
    >> Share

  38. ZHANG X, Yip TC, Wong GL, Leow WX, et al
    Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.
    Gut. 2023;72:2364-2371.
    >> Share

  39. RODERBURG C, Kostev K, Mertens A, Luedde T, et al
    Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of extrahepatic cancer.
    Gut. 2023;72:2383-2384.
    >> Share

  40. EN LI CHO E, Ang CZ, Quek J, Fu CE, et al
    Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
    Gut. 2023;72:2138-2148.
    >> Share


  41. Correction: Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
    Gut. 2023;72:e4.
    >> Share

    October 2023
  42. BRENNAN PN, Zelber-Sagi S, Allen AM, Dillon JF, et al
    Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm.
    Gut. 2023 Oct 28:gutjnl-2023-330771. doi: 10.1136/gutjnl-2023-330771.
    >> Share

  43. ARECHEDERRA M, Casadei Gardini A, Raggi C
    More than shots in the dark: improving patient stratification to move closer to personalised therapies in intrahepatic cholangiocarcinoma.
    Gut. 2023 Oct 27:gutjnl-2023-331119. doi: 10.1136/gutjnl-2023-331119.
    >> Share

  44. JUANOLA A, Ma AT, de Wit K, Gananandan K, et al
    Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.
    Gut. 2023 Oct 26:gutjnl-2023-329923. doi: 10.1136/gutjnl-2023-329923.
    >> Share

  45. TESTONI B, Scholtes C, Plissonnier ML, Paturel A, et al
    Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
    Gut. 2023 Oct 25:gutjnl-2023-330644. doi: 10.1136/gutjnl-2023-330644.
    >> Share

  46. CHOI WM, Kim GA, Choi J, Choi GH, et al
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
    >> Share

  47. MUKHOPADHYA I
    Is HBx protein the X factor in the pathogenesis of IBD?
    Gut. 2023;72:1808-1809.
    >> Share

  48. CIOCAN D, Turpin W
    New insights into an old paradigm: why IgA accumulates in alcoholic liver disease and what could be its role.
    Gut. 2023;72:1812-1814.
    >> Share

  49. AVILA MA
    MicroRNA-223: a key regulator of liver tumour microenvironment.
    Gut. 2023;72:1811-1812.
    >> Share

    September 2023
  50. MANTOVANI A, Tilg H, Targher G
    FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials.
    Gut. 2023 Sep 27:gutjnl-2023-331115. doi: 10.1136/gutjnl-2023-331115.
    >> Share

  51. O'ROURKE CJ, Salati M, Rae C, Carpino G, et al
    Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
    Gut. 2023 Sep 27:gutjnl-2023-330748. doi: 10.1136/gutjnl-2023-330748.
    >> Share

  52. RAMADORI P, Gallage S, Heikenwalder MF
    Unique tumour microenvironment: when ferroptosis activation boosts ICI of liver cancer.
    Gut. 2023;72:1639-1641.
    >> Share

  53. LUXENBURGER H, Thimme R
    SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease.
    Gut. 2023;72:1783-1794.
    >> Share

  54. CONCHE C, Finkelmeier F, Pesic M, Nicolas AM, et al
    Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade.
    Gut. 2023;72:1774-1782.
    >> Share

    August 2023
  55. FAN Z, Jin M, Zhang L, Wang N, et al
    From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification.
    Gut. 2023 Aug 7:gutjnl-2023-330461. doi: 10.1136/gutjnl-2023-330461.
    >> Share

  56. MARJOT T, Tomlinson JW, Hodson L, Ray DW, et al
    Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD.
    Gut. 2023;72:1607-1619.
    >> Share

  57. GRETEN TF
    'Invisible' immune checkpoint molecule causing resistance to anti-PD1 therapy in HCC.
    Gut. 2023;72:1440-1441.
    >> Share

    July 2023
  58. ZHAO L, Wu Q, Li Q, Chen A, et al
    TIPSS plus extrahepatic collateral embolisation may decrease variceal rebleeding and post-TIPSS hepatic encephalopathy.
    Gut. 2023 Jul 31:gutjnl-2023-330255. doi: 10.1136/gutjnl-2023-330255.
    >> Share

  59. HE X, Gao N, Lv F, Wu F, et al
    Temporal trend of mortality in patients with cirrhosis with primary biliary cholangitis and primary sclerosing cholangitis during the COVID-19 pandemic.
    Gut. 2023 Jul 24:gutjnl-2023-330271. doi: 10.1136/gutjnl-2023-330271.
    >> Share

  60. WANG X, Huang H, Sze KM, Wang J, et al
    S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos.
    Gut. 2023;72:1370-1384.
    >> Share

  61. MANTOVANI A, Csermely A, Tilg H, Byrne CD, et al
    Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals.
    Gut. 2023;72:1433-1436.
    >> Share

  62. BYRNE CD, Targher G
    Time to consider a holistic approach to the treatment of non-alcoholic fatty liver disease in obese young people?
    Gut. 2023;72:1238-1239.
    >> Share

    June 2023
  63. POTENZA A, Balestrieri C, Spiga M, Albarello L, et al
    Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.
    Gut. 2023 Jun 30:gutjnl-2022-328042. doi: 10.1136/gutjnl-2022-328042.
    >> Share

  64. WITTKOP L, Boettler T
    More than shots in the dark: driving vaccine efficacy in cirrhosis.
    Gut. 2023 Jun 7:gutjnl-2023-329867. doi: 10.1136/gutjnl-2023-329867.
    >> Share

  65. FISCHER A, Ozdirik B, Geisel D, Malinka T, et al
    Gastric variceal bleeding in a patient with alcohol abuse: business as usual?
    Gut. 2023;72:1038-1114.
    >> Share

    May 2023
  66. ZHANG Q, Ye M, Lin C, Hu M, et al
    Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study.
    Gut. 2023;72:996-1006.
    >> Share

    April 2023
  67. LEWINSKA M, Karhus ML, Ellegaard AG, Romero-Gomez M, et al
    Serum lipidome unravels a diagnostic potential in bile acid diarrhoea.
    Gut. 2023 Apr 18:gutjnl-2022-329213. doi: 10.1136/gutjnl-2022-329213.
    >> Share

  68. XIONG Z, Chan SL, Zhou J, Vong JSL, et al
    Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma.
    Gut. 2023 Apr 5:gutjnl-2022-328364. doi: 10.1136/gutjnl-2022-328364.
    >> Share

    March 2023
  69. GIRALDEZ-GALLEGO A, Rodriguez-Seguel EDP, Valencia-Martin R, Morillo-Garcia A, et al
    Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial.
    Gut. 2023 Mar 24:gutjnl-2022-328222. doi: 10.1136/gutjnl-2022-328222.
    >> Share

  70. CAMILLERI M, El-Omar EM
    Ten reasons gastroenterologists and hepatologists should be treating obesity.
    Gut. 2023 Mar 21:gutjnl-2023-329639. doi: 10.1136/gutjnl-2023-329639.
    >> Share

  71. LOOMBA R, Huang DQ, Sanyal AJ, Anstee QM, et al
    Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
    Gut. 2023;72:581-589.
    >> Share

  72. SIMON TG, Roelstraete B, Alkhouri N, Hagstrom H, et al
    Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease.
    Gut. 2023;72:573-580.
    >> Share

  73. WANG S, Feng R, Wang SS, Liu H, et al
    FOXA2 prevents hyperbilirubinaemia in acute liver failure by maintaining apical MRP2 expression.
    Gut. 2023;72:549-559.
    >> Share

    February 2023
  74. WEISS E, de la Pena-Ramirez C, Aguilar F, Lozano JJ, et al
    Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
    Gut. 2023 Feb 14:gutjnl-2022-328708. doi: 10.1136/gutjnl-2022-328708.
    >> Share

  75. KANE SV, Reau N
    Clinical advances: pregnancy in gastroenterologic and hepatic conditions.
    Gut. 2023 Feb 9:gutjnl-2022-328893. doi: 10.1136/gutjnl-2022-328893.
    >> Share

    January 2023
  76. HENDRIKX T, Lang S, Rajcic D, Wang Y, et al
    Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice.
    Gut. 2023 Jan 23:gutjnl-2022-328265. doi: 10.1136/gutjnl-2022-328265.
    >> Share

  77. RAVAIOLI F, Dajti E, Mantovani A, Newsome PN, et al
    Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.
    Gut. 2023 Jan 4:gutjnl-2022-328689. doi: 10.1136/gutjnl-2022-328689.
    >> Share

  78. CHEN S, Huang C, Liao G, Sun H, et al
    Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences.
    Gut. 2023 Jan 3:gutjnl-2022-328428. doi: 10.1136/gutjnl-2022-328428.
    >> Share

  79. FU Y, Mackowiak B, Feng D, Lu H, et al
    MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression.
    Gut. 2023 Jan 2:gutjnl-2022-327924. doi: 10.1136/gutjnl-2022-327924.
    >> Share

  80. ITZEL T, Falconer T, Daza J, Roig A, et al
    Letter to the editor: vaccination against upper respiratory infections is a matter of survival in alcoholic liver disease.
    Gut. 2023;72:208-209.
    >> Share

  81. MONTIRONI C, Castet F, Haber PK, Pinyol R, et al
    Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
    Gut. 2023;72:129-140.
    >> Share

  82. HERNAEZ R, Peck-Radosavljevic M
    MAFLD, HCC and the dilemma of (changing) terminology in liver diseases.
    Gut. 2023;72:9-11.
    >> Share

    December 2022
  83. LATIF MU, Schmidt GE, Mercan S, Rahman R, et al
    NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression.
    Gut. 2022;71:2561-2573.
    >> Share

  84. RAO J, Wang H, Ni M, Wang Z, et al
    FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2.
    Gut. 2022;71:2539-2550.
    >> Share

    November 2022
  85. TAN Z, Chiu MS, Yang X, Yue M, et al
    Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.
    Gut. 2022 Nov 30:gutjnl-2022-327133. doi: 10.1136/gutjnl-2022-327133.
    >> Share

  86. BAJAJ JS, Pena-Rodriguez M, La Reau A, Phillips W, et al
    Longitudinal transkingdom gut microbial approach towards decompensation in outpatients with cirrhosis.
    Gut. 2022 Nov 7. pii: gutjnl-2022-328403. doi: 10.1136/gutjnl-2022-328403.
    >> Share

  87. THEVENOT T, Desmarets M, Weil D, Di Martino V, et al
    Diameter of the shunt: the missing link in the appraisal of pTIPS in patients with cirrhosis with previous hepatic encephalopathy.
    Gut. 2022 Nov 3. pii: gutjnl-2022-328761. doi: 10.1136/gutjnl-2022-328761.
    >> Share

  88. DUFOUR JF, Marjot T, Becchetti C, Tilg H, et al
    COVID-19 and liver disease.
    Gut. 2022;71:2350-2362.
    >> Share

  89. KASPER P, Lang S, Demir M, Steffen HM, et al
    Optimising the management of cardiovascular comorbidities in NAFLD patients: it's time to (re-) act!
    Gut. 2022;71:2365-2366.
    >> Share

    September 2022
  90. KULKARNI AV, Metage CS, Gora BA, Tirumalle S, et al
    SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis.
    Gut. 2022 Sep 16. pii: gutjnl-2022-328451. doi: 10.1136/gutjnl-2022-328451.
    >> Share

  91. RUDLER M, Hernandez-Gea V, Procopet BD, Giraldez A, et al
    Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding.
    Gut. 2022 Sep 9. pii: gutjnl-2022-326975. doi: 10.1136/gutjnl-2022-326975.
    >> Share

  92. LI X, Pan J, Liu T, Yin W, et al
    Novel TCF21(high) pericyte subpopulation promotes colorectal cancer metastasis by remodelling perivascular matrix.
    Gut. 2022 Sep 7:gutjnl-2022-327913. doi: 10.1136/gutjnl-2022-327913.
    >> Share

  93. ZHAO Y, Yeo YH, Samaan J, Lv F, et al
    Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19.
    Gut. 2022 Sep 5. pii: gutjnl-2022-328188. doi: 10.1136/gutjnl-2022-328188.
    >> Share

  94. JOHN BV, Bastaich DR, Ferreira RD, Doshi A, et al
    COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis.
    Gut. 2022 Sep 5:gutjnl-2022-327799. doi: 10.1136/gutjnl-2022-327799.
    >> Share

  95. BYRNE CD, Targher G
    Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed.
    Gut. 2022;71:1695-1696.
    >> Share

  96. SIMON TG, Roelstraete B, Hagstrom H, Sundstrom J, et al
    Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
    Gut. 2022;71:1867-1875.
    >> Share

    August 2022

  97. Correction: Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2022;71:e9.
    >> Share

  98. LIU N, Wang X, Steer CJ, Song G, et al
    MicroRNA-206 promotes the recruitment of CD8(+) T cells by driving M1 polarisation of Kupffer cells.
    Gut. 2022;71:1642-1655.
    >> Share

  99. ZHOU L, Yu KH, Wong TL, Zhang Z, et al
    Lineage tracing and single-cell analysis reveal proliferative Prom1+ tumour-propagating cells and their dynamic cellular transition during liver cancer progression.
    Gut. 2022;71:1656-1668.
    >> Share

  100. REVIA S, Seretny A, Wendler L, Banito A, et al
    Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
    Gut. 2022;71:1613-1628.
    >> Share

  101. LAUER GM
    Omics studies in gastroenterological and hepatological patient populations: current impact and future promise exemplified by a large study of HCV-infected livers.
    Gut. 2022 Aug 1. pii: gutjnl-2022-327761. doi: 10.1136/gutjnl-2022-327761.
    >> Share

    July 2022
  102. MONIN MB, Baier L, Berger M, Gorny JG, et al
    SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination.
    Gut. 2022 Jul 26. pii: gutjnl-2022-328169. doi: 10.1136/gutjnl-2022-328169.
    >> Share

  103. ANGELINI G, Panunzi S, Castagneto-Gissey L, Pellicano F, et al
    Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.
    Gut. 2022 Jul 12. pii: gutjnl-2022-327498. doi: 10.1136/gutjnl-2022-327498.
    >> Share

  104. BUCH S, Innes H, Lutz PL, Nischalke HD, et al
    Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study.
    Gut. 2022 Jul 4. pii: gutjnl-2022-327196. doi: 10.1136/gutjnl-2022-327196.
    >> Share

  105. GRACIA-SANCHO J, Dufour JF
    NTCP: a pharmacological target for multiple liver conditions.
    Gut. 2022;71:1248-1250.
    >> Share

  106. PAVLIDES M, Mozes FE, Harrison SA
    Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1453-1454.
    >> Share

  107. SALHAB A, Amer J, Lu Y, Safadi R, et al
    Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.
    Gut. 2022;71:1373-1385.
    >> Share

    June 2022
  108. MORITA S, Duda DG
    Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?
    Gut. 2022 Jun 30. pii: gutjnl-2022-327782. doi: 10.1136/gutjnl-2022-327782.
    >> Share

  109. BEA S, Jeong HE, Park S, Yu OHY, et al
    Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study.
    Gut. 2022 Jun 20. pii: gutjnl-2022-327504. doi: 10.1136/gutjnl-2022-327504.
    >> Share

  110. AWONIYI M, Wang J, Ngo B, Meadows V, et al
    Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
    Gut. 2022 Jun 15. pii: gutjnl-2021-326500. doi: 10.1136/gutjnl-2021-326500.
    >> Share

  111. MITHIEUX G
    Transcription factor p63, a member of the p53 family of tumour suppressors, regulates hepatic glucose metabolism.
    Gut. 2022 Jun 15. pii: gutjnl-2022-327790. doi: 10.1136/gutjnl-2022-327790.
    >> Share

  112. SULLIVAN KM, Jiang X, Guha P, Lausted C, et al
    Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases.
    Gut. 2022 Jun 15. pii: gutjnl-2021-325808. doi: 10.1136/gutjnl-2021-325808.
    >> Share

  113. UCHE-ANYA E, Anyane-Yeboa A, Berzin TM, Ghassemi M, et al
    Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity.
    Gut. 2022 Jun 10. pii: gutjnl-2021-326271. doi: 10.1136/gutjnl-2021-326271.
    >> Share

  114. MAJUMDAR A, Tsochatzis EA
    Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1236-1237.
    >> Share

    May 2022
  115. MARCHI E, Ramamurthy N, Ansari MA, Harrer CE, et al
    Defining the key intrahepatic gene networks in HCV infection driven by sex.
    Gut. 2022 May 25. pii: gutjnl-2021-326314. doi: 10.1136/gutjnl-2021-326314.
    >> Share

  116. DHAR A, Haboubi HN, Attwood SE, Auth MKH, et al
    British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults.
    Gut. 2022 May 23. pii: gutjnl-2022-327326. doi: 10.1136/gutjnl-2022-327326.
    >> Share

  117. MARTIN-SERRANO MA, Kepecs B, Torres-Martin M, Bramel ER, et al
    Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Gut. 2022 May 18. pii: gutjnl-2021-326514. doi: 10.1136/gutjnl-2021-326514.
    >> Share

  118. GONZALEZ-RELLAN MJ, Novoa E, da Silva Lima N, Rodriguez A, et al
    Hepatic p63 regulates glucose metabolism by repressing SIRT1.
    Gut. 2022 May 17. pii: gutjnl-2021-326620. doi: 10.1136/gutjnl-2021-326620.
    >> Share

  119. RIVOLTINI L, Bhoori S, Camisaschi C, Bergamaschi L, et al
    Y(90)-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers.
    Gut. 2022 May 4. pii: gutjnl-2021-326869. doi: 10.1136/gutjnl-2021-326869.
    >> Share

  120. MOZES FE, Lee JA, Selvaraj EA, Jayaswal ANA, et al
    Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
    Gut. 2022;71:1006-1019.
    >> Share

  121. TAMAKI N, Munaganuru N, Jung J, Yonan AQ, et al
    Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
    Gut. 2022;71:983-990.
    >> Share

    April 2022
  122. HERNAEZ R, Avila MA
    Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono?
    Gut. 2022 Apr 26. pii: gutjnl-2022-327132. doi: 10.1136/gutjnl-2022-327132.
    >> Share

  123. ZHAO Y, Ren X, Lu J, He M, et al
    Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids.
    Gut. 2022 Apr 22. pii: gutjnl-2021-326617. doi: 10.1136/gutjnl-2021-326617.
    >> Share

  124. HOHMANN N, Schroder F, Moreira B, Teng H, et al
    Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease.
    Gut. 2022;71:842-844.
    >> Share

  125. SMATI S, Polizzi A, Fougerat A, Ellero-Simatos S, et al
    Integrative study of diet-induced mouse models of NAFLD identifies PPARalpha as a sexually dimorphic drug target.
    Gut. 2022;71:807-821.
    >> Share

  126. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
    Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies.
    Gut. 2022;71:778-788.
    >> Share

    March 2022
  127. ZHANG C, Li J, Cheng Y, Meng F, et al
    Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients.
    Gut. 2022 Mar 31. pii: gutjnl-2021-325915. doi: 10.1136/gutjnl-2021-325915.
    >> Share

  128. JUANOLA A, Mezzano G, Hamilton JP, Gines P, et al
    Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data".
    Gut. 2022;71:657-658.
    >> Share

  129. HADERER M, Neubert P, Rinner E, Scholtis A, et al
    Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases.
    Gut. 2022;71:580-592.
    >> Share

  130. RHA MS, Han JW, Koh JY, Lee HS, et al
    Impaired antibacterial response of liver sinusoidal Vgamma9(+)Vdelta2(+) T cells in patients with chronic liver disease.
    Gut. 2022;71:605-615.
    >> Share

    February 2022
  131. LU LG, Zhou ZL, Wang XY, Liu BY, et al
    PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma.
    Gut. 2022 Feb 16. pii: gutjnl-2021-326350. doi: 10.1136/gutjnl-2021-326350.
    >> Share

  132. SUN S, Yang Q, Zhou Q, Cao W, et al
    Long-term exposure to fine particulate matter and non-alcoholic fatty liver disease: a prospective cohort study.
    Gut. 2022;71:443-445.
    >> Share

  133. CAO Z, Xie Q
    Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data.
    Gut. 2022;71:445-446.
    >> Share

  134. FRANCQUE S, Wong VW
    NAFLD in lean individuals: not a benign disease.
    Gut. 2022;71:234-236.
    >> Share

  135. YOUNES R, Govaere O, Petta S, Miele L, et al
    Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
    Gut. 2022;71:382-390.
    >> Share

  136. TREBICKA J, Gu W, de Ledinghen V, Aube C, et al
    Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease.
    Gut. 2022;71:402-414.
    >> Share

    January 2022
  137. TIAN S, Chu Y, Hu J, Ding X, et al
    Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc-xCT.
    Gut. 2022 Jan 27. pii: gutjnl-2021-325137. doi: 10.1136/gutjnl-2021-325137.
    >> Share

  138. SONDERGAARD JN, Sommerauer C, Atanasoai I, Hinte LC, et al
    CCT3-LINC00326 axis regulates hepatocarcinogenic lipid metabolism.
    Gut. 2022 Jan 12. pii: gutjnl-2021-325109. doi: 10.1136/gutjnl-2021-325109.
    >> Share

  139. BELLOMO G, Rainer C, Quaranta V, Astuti Y, et al
    Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis.
    Gut. 2022 Jan 12. pii: gutjnl-2021-325272. doi: 10.1136/gutjnl-2021-325272.
    >> Share

  140. JI F, Zhang J, Liu N, Gu Y, et al
    Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression.
    Gut. 2022 Jan 7. pii: gutjnl-2021-326050. doi: 10.1136/gutjnl-2021-326050.
    >> Share

  141. SCHULZ M, Trebicka J
    Acute-on-chronic liver failure: a global disease.
    Gut. 2022;71:5-6.
    >> Share

  142. MEZZANO G, Juanola A, Cardenas A, Mezey E, et al
    Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis.
    Gut. 2022;71:148-155.
    >> Share

  143. MANTOVANI A, Petracca G, Beatrice G, Csermely A, et al
    Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.
    Gut. 2022;71:156-162.
    >> Share

    December 2021
  144. VITALE A, Svegliati-Baroni G, Ortolani A, Cucco M, et al
    Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
    Gut. 2021 Dec 21. pii: gutjnl-2021-324915. doi: 10.1136/gutjnl-2021-324915.
    >> Share

  145. HUNG CT, Su TH, Chen YT, Wu YF, et al
    Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling.
    Gut. 2021 Dec 21. pii: gutjnl-2021-325065. doi: 10.1136/gutjnl-2021-325065.
    >> Share

  146. MACKEN L, Palaniyappan N, Verma S, Aithal G, et al
    Large volume paracentesis: to do or where to do?
    Gut. 2021;70:2401-2402.
    >> Share

  147. BANG JY, Ward TJ, Guirguis S, Krall K, et al
    Radiology-guided percutaneous approach is superior to EUS for performing liver biopsies.
    Gut. 2021;70:2224-2226.
    >> Share

  148. ARNORIAGA-RODRIGUEZ M, Mayneris-Perxachs J, Contreras-Rodriguez O, Burokas A, et al
    Obesity-associated deficits in inhibitory control are phenocopied to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic pathways.
    Gut. 2021;70:2283-2296.
    >> Share

  149. AFONSO MB, Rodrigues PM, Mateus-Pinheiro M, Simao AL, et al
    RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
    Gut. 2021;70:2359-2372.
    >> Share

  150. CARGILL Z, Cargill T, Lei B, Bekkali N, et al
    Uphill or downhill bleeding?
    Gut. 2021;70:2282-2348.
    >> Share

    November 2021
  151. LIU DS, Frampton AE
    Plasma extracellular vesicles contain unannotated small RNA clusters suitable as biomarkers for detecting early hepatocellular carcinoma.
    Gut. 2021 Nov 19. pii: gutjnl-2021-325798. doi: 10.1136/gutjnl-2021-325798.
    >> Share

    October 2021
  152. TRAUNER M, Fuchs CD
    Novel therapeutic targets for cholestatic and fatty liver disease.
    Gut. 2021 Oct 6. pii: gutjnl-2021-324305. doi: 10.1136/gutjnl-2021-324305.
    >> Share


  153. Correction: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2.
    Gut. 2021;70:e7.
    >> Share

  154. WEBER S, Hellmuth JC, Scherer C, Muenchhoff M, et al
    Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study.
    Gut. 2021;70:1925-1932.
    >> Share

  155. LIU T, Tan J, Wu M, Fan W, et al
    High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39(+)CD8(+) T cells.
    Gut. 2021;70:1965-1977.
    >> Share

  156. JUNG J, Loomba RR, Imajo K, Madamba E, et al
    MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Gut. 2021;70:1946-1953.
    >> Share

  157. MANKA P, Baba HA, Wedemeyer H, Kahraman A, et al
    Diet-refractory NASH in an elderly woman.
    Gut. 2021;70:1924-1945.
    >> Share

    September 2021
  158. AN J, Kim HI, Oh B, Oh YJ, et al
    Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study.
    Gut. 2021 Sep 7. pii: gutjnl-2021-325844. doi: 10.1136/gutjnl-2021-325844.
    >> Share

  159. JACHS M, Hartl L, Schaufler D, Desbalmes C, et al
    Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.
    Gut. 2021;70:1758-1767.
    >> Share

    August 2021
  160. KHAMRI W, Gudd C, Liu T, Nathwani R, et al
    Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis.
    Gut. 2021 Aug 3. pii: gutjnl-2021-324071. doi: 10.1136/gutjnl-2021-324071.
    >> Share

  161. LIU J, Geng W, Sun H, Liu C, et al
    Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma.
    Gut. 2021 Aug 3. pii: gutjnl-2021-325189. doi: 10.1136/gutjnl-2021-325189.
    >> Share

  162. HEINRICH B, Gertz EM, Schaffer AA, Craig A, et al
    The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma.
    Gut. 2021 Aug 2. pii: gutjnl-2021-325288. doi: 10.1136/gutjnl-2021-325288.
    >> Share

    July 2021
  163. SHENG J, Zhang J, Wang L, Tano V, et al
    Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.
    Gut. 2021 Jul 12. pii: gutjnl-2021-324339. doi: 10.1136/gutjnl-2021-324339.
    >> Share

  164. SIMON TG, Roelstraete B, Khalili H, Hagstrom H, et al
    Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Gut. 2021;70:1375-1382.
    >> Share

  165. WRZOSEK L, Ciocan D, Hugot C, Spatz M, et al
    Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury.
    Gut. 2021;70:1299-1308.
    >> Share

    June 2021
  166. PARK H, Yoon EL, Cho S, Jun DW, et al
    Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
    Gut. 2021 Jun 14. pii: gutjnl-2021-325102. doi: 10.1136/gutjnl-2021-325102.
    >> Share

  167. CHEUNG CCL, Goh D, Lim X, Tien TZ, et al
    Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2021 Jun 2. pii: gutjnl-2021-324280. doi: 10.1136/gutjnl-2021-324280.
    >> Share

    May 2021
  168. SUN J, Wu G, Pastor F, Rahman N, et al
    RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
    Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
    >> Share

  169. ARMANDI A, Schattenberg JM
    NAFLD between genes and environment: what drives fibrogenesis?
    Gut. 2021;70:815-816.
    >> Share

  170. MANTOVANI A, Petracca G, Beatrice G, Tilg H, et al
    Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.
    Gut. 2021;70:962-969.
    >> Share

    April 2021
  171. XIE Z, Gao Y, Ho C, Li L, et al
    Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.
    Gut. 2021 Apr 7. pii: gutjnl-2020-323014. doi: 10.1136/gutjnl-2020-323014.
    >> Share

  172. WANG X, He Y, Mackowiak B, Gao B, et al
    MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.
    Gut. 2021;70:784-795.
    >> Share

  173. ZHANG X, Coker OO, Chu ES, Fu K, et al
    Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
    Gut. 2021;70:761-774.
    >> Share

    March 2021
  174. GRANDER C, Schaefer B, Schwarzler J, Grabherr F, et al
    Alpha-1 antitrypsin governs alcohol-related liver disease in mice and humans.
    Gut. 2021;70:585-594.
    >> Share

    February 2021
  175. CHEN HN, Shu Y, Liao F, Liao X, et al
    Genomic evolution and diverse models of systemic metastases in colorectal cancer.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323703. doi: 10.1136/gutjnl-2020-323703.
    >> Share

  176. GOESER F, Munch P, Lesker TR, Lutz PL, et al
    Neither black nor white: do altered intestinal microbiota reflect chronic liver disease severity?
    Gut. 2021;70:438-440.
    >> Share

  177. BARCENA-VARELA M, Paish H, Alvarez L, Uriarte I, et al
    Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.
    Gut. 2021;70:388-400.
    >> Share

    January 2021
  178. BELLINGHAUSEN C, Pletz MW, Rupp J, Witzenrath M, et al
    Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia.
    Gut. 2021;70:221-222.
    >> Share

  179. PETROFF D, Batz O, Jedrysiak K, Kramer J, et al
    Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples.
    Gut. 2021;70:219-221.
    >> Share

  180. TANAKA Y, Shimanaka Y, Caddeo A, Kubo T, et al
    LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover.
    Gut. 2021;70:180-193.
    >> Share

  181. HAGSTROM H, Thiele M, Roelstraete B, Soderling J, et al
    Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.
    Gut. 2021;70:170-179.
    >> Share

    December 2020
  182. VILY-PETIT J, Soty-Roca M, Silva M, Raffin M, et al
    Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease.
    Gut. 2020;69:2193-2202.
    >> Share

    November 2020
  183. FROST F, Kacprowski T, Ruhlemann M, Pietzner M, et al
    Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function.
    Gut. 2020 Nov 9. pii: gutjnl-2020-322753. doi: 10.1136/gutjnl-2020-322753.
    >> Share

  184. LYU Z, Miao Q, Jiang P, Xiao X, et al
    Unexplained liver dysfunction in a young Chinese man with eosinophilia.
    Gut. 2020;69:1938-1987.
    >> Share

    October 2020
  185. BASELLI GA, Dongiovanni P, Rametta R, Meroni M, et al
    Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker.
    Gut. 2020;69:1855-1866.
    >> Share

  186. PIRONI L, Steiger E, Joly F, Wanten GJA, et al
    Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure.
    Gut. 2020;69:1787-1795.
    >> Share

    September 2020
  187. TARGHER G, Byrne CD, Tilg H
    NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.
    Gut. 2020;69:1691-1705.
    >> Share

  188. SZAFRON D, Kim HS, Turin CG, Benzi E, et al
    Duodenal and liver lesions in an adult with generalised weakness.
    Gut. 2020;69:1-2.
    >> Share

    February 2020
  189. SALERNO D, Chiodo L, Alfano V, Floriot O, et al
    Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319637. doi: 10.1136/gutjnl-2019-319637.
    >> Share

    January 2020
  190. DROPMANN A, Dooley S, Dewidar B, Hammad S, et al
    TGF-beta2 silencing to target biliary-derived liver diseases.
    Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016